CLBT vs. NABL, LSPD, INST, MQ, COUR, AVPT, MTTR, MLNK, ZETA, and AMPL
Should you be buying Cellebrite DI stock or one of its competitors? The main competitors of Cellebrite DI include N-able (NABL), Lightspeed Commerce (LSPD), Instructure (INST), Marqeta (MQ), Coursera (COUR), AvePoint (AVPT), Matterport (MTTR), MeridianLink (MLNK), Zeta Global (ZETA), and Amplitude (AMPL). These companies are all part of the "prepackaged software" industry.
Cellebrite DI (NASDAQ:CLBT) and N-able (NYSE:NABL) are both mid-cap business services companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, community ranking, media sentiment and analyst recommendations.
N-able has a net margin of 6.27% compared to Cellebrite DI's net margin of -24.94%. Cellebrite DI's return on equity of 173.14% beat N-able's return on equity.
Cellebrite DI received 7 more outperform votes than N-able when rated by MarketBeat users. However, 62.07% of users gave N-able an outperform vote while only 53.19% of users gave Cellebrite DI an outperform vote.
45.9% of Cellebrite DI shares are held by institutional investors. Comparatively, 96.4% of N-able shares are held by institutional investors. 5.7% of Cellebrite DI shares are held by insiders. Comparatively, 1.4% of N-able shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Cellebrite DI has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, N-able has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500.
In the previous week, N-able had 4 more articles in the media than Cellebrite DI. MarketBeat recorded 9 mentions for N-able and 5 mentions for Cellebrite DI. Cellebrite DI's average media sentiment score of 1.52 beat N-able's score of 0.68 indicating that Cellebrite DI is being referred to more favorably in the media.
Cellebrite DI currently has a consensus price target of $12.42, indicating a potential upside of 12.37%. N-able has a consensus price target of $15.50, indicating a potential upside of 22.63%. Given N-able's higher probable upside, analysts clearly believe N-able is more favorable than Cellebrite DI.
N-able has higher revenue and earnings than Cellebrite DI. Cellebrite DI is trading at a lower price-to-earnings ratio than N-able, indicating that it is currently the more affordable of the two stocks.
Summary
Cellebrite DI and N-able tied by winning 9 of the 18 factors compared between the two stocks.
Get Cellebrite DI News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLBT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cellebrite DI Competitors List
Related Companies and Tools
